Stock Analysts

G-III Lags, Trims EPS Outlook (CROX) (GIII) (RL)

New York-based G-III Apparel Group, Ltd ( GIII ) posted earnings per share of 8 cents in the second quarter of fiscal 2012, missing the Zacks Consensus Estimate of 20 cents and the year-ago quarter earnings of 15 cents per share. The lower-than-expected result was mainly due to margin contraction. […]

Stock Analysts

Marcus Reports Strong 1Q (HTHT) (IHG) (MCS)

Milwaukee-based The Marcus Corporation ( MCS ) reported first quarter 2012 earnings of 42 cents per share, beating the Zacks Consensus Estimate of 40 cents and the year-earlier quarter earnings of 34 cents per share. The entertainment and lodging company’s revenues were up 8.7% year over year to $123.9 million. The increase in revenue was due to record performance by the company’s movie theater division, Marcus Theater, as well as the lodging division, Marcus Hotels and Resorts. […]

Stock Analysts

Deckers Poised Between Risk-Reward (DECK) (NKE)

Strong demand for the UGG brand product line, product introductions and in-demand inventory has helped Deckers Outdoor Corporation ( DECK ) to carve a niche in the footwear and accessories market for outdoor sports. We believe that growth of UGG and Teva brands will lead to increase in sales. Deckers anticipates its UGG brand sales to increase approximately 25% and Teva brand sales to increase in the low-20's in 2011, while other brand sales are expected to remain flat with the prior year. […]

Technicals

Bearish MACD for Brady Corporation – Tale of the Tape (BRC)

Brady Corporation ’s ( BRC ) MACD indicator has moved into bearish territory with a reading of -0.0390. The Zacks #4 Rank (“Sell”) stock decreased slightly to $26.82 in morning trade. The Zacks Consensus Estimate on the company’s earnings for the year ending July 2012 has decreased by 11 cents over the past month to $2.39 per share […]

Technicals

Bearish MACD for NXPI – Tale of the Tape (NXPI)

NXP Semiconductors NV ’s ( NXPI ) MACD indicator has entered into bearish territory with a reading of -0.0963. The Zacks #5 Rank (“Strong Sell”) stock decreased more than 4% to $16.42 in morning trade. The Zacks Consensus Estimate for the year ending December 2011 has decreased by a cent over the past month to $2.02 per share. […]

Stock Analysts

RXi Licenses Novel, Targeted Cancer Vaccine for Gynecological Cancers (RXII)

RXi Licenses Novel, Targeted Cancer Vaccine for Gynecological Cancers Grant Zeng, CFA On September 21, 2011, RXi Pharmaceuticals Corporation ( RXII ) announced that it has licensed worldwide rights to develop and commercialize a Folate Binding Protein-E39 ( FBP ) targeted vaccine to prevent recurrence in gynecological cancers such as ovarian and endometrial adenocarcinomas. The FBP vaccine was licensed from The University of Texas M D Anderson Cancer Center and Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. […]

Stock Analysts

FactSet Beats by a Penny (FDS) (MSCI)

FactSet Research ( FDS ) reported fourth quarter 2011 earnings per share (EPS) of 96 cents, exceeding the Zacks Consensus Estimate by a penny. Revenue The company reported total revenue of $191.9 million in the fourth quarter of 2011, up 14.1% from $168.2 million delivered in the year-ago quarter, mainly attributed to the improvement in the annual subscription value and client count. U.S.revenues expanded 15.0% year over year to $132.0 million […]